Login / Signup

Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis.

Donald C MooreJoseph B ElmesJustin R ArnallScott A StrasselsJai N Patel
Published in: International journal of clinical pharmacy (2023)
Overall, our analysis demonstrates a significant reporting signal for HBV reactivation with daratumumab and isatuximab.
Keyphrases
  • multiple myeloma
  • monoclonal antibody
  • adverse drug
  • emergency department